Infant respiratory distress syndrome
Infantile Respiratory Distress Syndrome (IRDS)[edit | edit source]
Infantile Respiratory Distress Syndrome (IRDS), also known as respiratory distress syndrome of newborns or surfactant deficiency disorder (SDD), is a serious condition affecting premature infants. It results from insufficient production of pulmonary surfactant and structural immaturity in the lungs.
Definition and Overview[edit | edit source]
IRDS, formerly known as hyaline membrane disease (HMD), is primarily seen in premature infants. The syndrome is characterized by difficulty in breathing, resulting from the lack of surfactant, a fluid that helps the lungs stay open and reduces surface tension in the alveoli.
Pathophysiology[edit | edit source]
The primary cause of IRDS is the underdevelopment of the lungs, particularly the lack of surfactant. Surfactant is essential for reducing surface tension within the alveoli and for keeping the lungs expanded.
Surfactant Insufficiency[edit | edit source]
- Lack of surfactant leads to alveolar collapse
- Results in compromised oxygen exchange
Lung Immaturity[edit | edit source]
- Structural immaturity in the lungs of premature infants
- Inability to maintain effective gas exchange
Clinical Manifestations[edit | edit source]
Symptoms of IRDS typically appear shortly after birth and may include:
- Rapid, shallow breathing
- Nasal flaring
- Chest wall retractions
- Grunting sounds
- Cyanosis (bluish skin color)
Diagnosis[edit | edit source]
Diagnosis of IRDS is based on:
- Clinical presentation
- Chest X-ray findings
- Blood gas analysis
Treatment and Management[edit | edit source]
Treatment of IRDS focuses on supporting the infant’s breathing and may include:
- Administration of supplemental oxygen
- Mechanical ventilation
- Surfactant replacement therapy
- Supportive care in a neonatal intensive care unit (NICU)
Epidemiology and Risk Factors[edit | edit source]
IRDS affects approximately 1% of newborns. Factors increasing the risk include:
- Prematurity
- Elective caesarean sections, which can increase incidence in term infants
- Genetic factors affecting surfactant production
Prevention and Prognosis[edit | edit source]
Preventive measures include:
- Administration of corticosteroids to the mother before preterm delivery
- Delaying elective caesarean sections until after 39 weeks of gestation
- The prognosis has improved significantly with advances in neonatal care.
Historical Perspective[edit | edit source]
Historically termed as hyaline membrane disease, the understanding and management of IRDS have evolved over the years, particularly with the development of surfactant therapy in the late 20th century.
References[edit | edit source]
Infant respiratory distress syndrome Resources | ||
---|---|---|
|
|
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Contributors: Kondreddy Naveen